Article
Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.
Seminars in arthritis and rheumatism - 1 Aug 2017
Sparks Jeffrey A, Barbhaiya Medha, Karlson Elizabeth W, Ritter Susan Y, Raychaudhuri Soumya, Corrigan Cassandra C, Lu Fengxin, Selhub Jacob, Chasman Daniel I, Paynter Nina P, Ridker Paul M, Solomon Daniel H
Abstract excerpt
BACKGROUND: The role of low dose methotrexate (LDM) in potential serious toxicities remains unclear despite its common use. Prior observational studies investigating LDM toxicity compared LDM to other active drugs. Prior placebo-controlled clinical trials of LDM in inflammatory conditions were not large enough to investigate toxicity. The Cardiovascular Inflammation Reduction Trial (CIRT) is an ongoing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.